References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.
- Fonseca R, Abouzaid S, Bonafede M, et al. Trends in overall survival and costs of multiple myeloma, 2000–2014. Leukemia. 2017;31:1915–1921.
- SEER. Surveillance, Epidemiology, and End Results (SEER) Program. 2020 [cited 2020 Mar 2]. Available from: https://seer.cancer.gov/statfacts/html/mulmy.html
- Mateos MV, San Miguel JF. How should we treat newly diagnosed multiple myeloma patients? Hematology Am Soc Hematol Educ Program. 2013;2013:488–495.
- Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–1128.
- Kazandjian D, Landgren O. A look backward and forward in the regulatory and treatment history of multiple myeloma: approval of novel-novel agents, new drug development, and longer patient survival. Semin Oncol. 2016;43:682–689.
- Tariman JD. Changes in cancer treatment: Mabs, Mibs, Mids, Nabs, and Nibs. Nurs Clin North Am. 2017;52:65–81.
- Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014;123:1826–1832.
- Larsen JT, Kumar S. Evolving paradigms in the management of multiple myeloma: novel agents and targeted therapies. Rare Cancers Ther. 2015;3:47–68.
- Moreau P, Sonneveld P, Boccadoro M, et al. Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. Haematologica. 2019;104:2358–2360.
- Shah N, Chari A, Scott E, et al. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34:985–1005.
- Varga C, Laubach JP, Anderson KC, et al. Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma. Br J Haematol. 2018;181:433–446.
- Song X, Cong Z, Wilson K. Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States. Curr Med Res Opin. 2016;32:95–103.
- Chen CC, Parikh K, Abouzaid S, et al. Real-world treatment patterns, time to next treatment, and economic outcomes in relapsed or refractory multiple myeloma patients treated with pomalidomide or carfilzomib. J Manag Care Spec Pharm. 2017;23:236–246.
- Flatiron Health EHR-derived database. [cited 2020 Mar 4]. Available from: https://flatiron.com/real-world-evidence/
- Kim C, Hernandez RK, Cyprien L, et al. Patterns of bisphosphonate treatment among patients with multiple myeloma treated at oncology clinics across the USA: observations from real-world data. Support Care Cancer. 2018;26:2833–2841.
- McGrath LJ, Hernandez RK, Overman R, et al. Initiation and interruption in intravenous bisphosphonate therapy among patients with multiple myeloma in the United States. Cancer Med. 2019;8:374–382.
- NCCN, National Comprehensive Cancer Network. Multiple Myeloma (Version 3.2020). 2020 [accessed 2020 Mar 12]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf
- Costa LJ, Brill IK, Omel J, et al. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Adv. 2017;1:282–287.
- Remes K, Anttila P, Silvennoinen R, et al. Real-world treatment outcomes in multiple myeloma: multicenter registry results from Finland 2009–2013. PloS One. 2018;13:e0208507.
- Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266–2275.
- Jagannath S, Abonour R, Durie BGM, et al. Heterogeneity of second-line treatment for patients with multiple myeloma in the Connect MM Registry (2010–2016). Clin Lymphoma Myeloma Leuk. 2018;18:480–485.e3.
- Prescribing information Kyprolis® (carfilzomib). Amgen Inc.; 2020. Available from: https://kyprolis.com
- Prescribing information Pomalyst® (pomalidomide). Celgene Corporation; 2020. Available from: https://media.celgene.com/content/uploads/pomalyst-pi.pdf
- Prescribing information Darzalex® (daratumumab). Janssen Biotech; 2020. Available from: https://www.darzalex.com/prescribing-information
- Prescribing information EMPLICITI® (elotuzumab). Bristol-Myers Squibb; 2019. Available from: https://packageinserts.bms.com/pi/pi_empliciti.pdf
- Prescribing information SARCLISA® (isatuximab-irfc). Sanofi-Aventis; 2020. Available from: http://products.sanofi.us/Sarclisa/sarclisa.pdf
- Prescribing information FARYDAK® (panobinostat). Secura Bio, Inc.; 2019. Available from: https://us.farydak.com/assets/pdf/Farydak-SBI-USPI-201909.pdf
- Curtis MD, Griffith SD, Tucker M, et al. Development and validation of a high-quality composite real-world mortality endpoint. Health Serv Res. 2018;53:4460–4476.